PCIDB

KNApSAcK Metabolite C00018636

Index

Metabolite

Species

Human Protein
/ Gene in interactions

Related Diseases

Metabolite

KNApSAcK Entry

id	C00018636
Name	CI 940 / Elactocin / Mantuamycin / Leptomycin B / Antibiotic CI 940 / Antibiotic CL 1957A
CAS RN	87081-35-4
Standard InChI	InChI=1S/C33H48O6/c1-9-28(14-15-29-24(5)13-16-31(36)39-29)19-22(3)12-10-11-21(2)17-25(6)32(37)27(8)33(38)26(7)18-23(4)20-30(34)35/h10-11,13-17,19-20,22,24-27,29,33,38H,9,12,18H2,1-8H3,(H,34,35)/b11-10+,15-14+,21-17+,23-20+,28-19-/t22-,24+,25-,26+,27-,29+,33-/m1/s1
Standard InChI (Main Layer)	InChI=1S/C33H48O6/c1-9-28(14-15-29-24(5)13-16-31(36)39-29)19-22(3)12-10-11-21(2)17-25(6)32(37)27(8)33(38)26(7)18-23(4)20-30(34)35/h10-11,13-17,19-20,22,24-27,29,33,38H,9,12,18H2,1-8H3,(H,34,35)

Cluster

Phytochemical cluster
KCF-S cluster	No. 1021

Link

ChEMBL

By standard InChI	CHEMBL486133
By standard InChI Main Layer	CHEMBL486133 CHEMBL2001508

KEGG

By LinkDB

CTD

By CAS RN	C038753

Species

Summary

Plant class

class name	count

Family

family name	count

List (1)

* NCBI

KNApSAcK organism	*ID	*family	*plant class	*kingdom
Actinomycete ATCC 39366

Human Protein / Gene in interaction

11 ChEMBL Protein in interactions

accession	description	class description	compound	assay ID (# of activities)	# of diseases (OMIM / KEGG)
P54132	Bloom syndrome protein	Enzyme	CHEMBL486133	CHEMBL1614067 (1)	1 / 2
P11473	Vitamin D3 receptor	NR1I1	CHEMBL486133	CHEMBL1794311 (1)	2 / 3
O15296	Arachidonate 15-lipoxygenase B	Enzyme	CHEMBL486133	CHEMBL1613800 (1)	0 / 0
P00352	Retinal dehydrogenase 1	Enzyme	CHEMBL486133	CHEMBL1614458 (1) CHEMBL1738585 (1)	0 / 0
P27695	DNA-(apurinic or apyrimidinic site) lyase	Enzyme	CHEMBL486133	CHEMBL1614211 (1)	0 / 0
O14980	Exportin-1	Unclassified protein	CHEMBL486133	CHEMBL940323 (1)	0 / 0
P46063	ATP-dependent DNA helicase Q1	Enzyme	CHEMBL486133	CHEMBL1613829 (1) CHEMBL1794433 (1)	0 / 0
Q96KQ7	Histone-lysine N-methyltransferase EHMT2	Enzyme	CHEMBL486133	CHEMBL1738442 (1)	0 / 0
Q9NUW8	Tyrosyl-DNA phosphodiesterase 1	Enzyme	CHEMBL486133	CHEMBL1614364 (1) CHEMBL1738394 (1)	1 / 1
Q13951	Core-binding factor subunit beta	Unclassified protein	CHEMBL486133	CHEMBL1613933 (1)	0 / 1
Q01196	Runt-related transcription factor 1	Unclassified protein	CHEMBL486133	CHEMBL1613933 (1)	1 / 6

CTD interaction (86)

compound	gene	gene name	gene description	interaction	interaction type	form	reference pmid
C038753	196	AHR bHLHe76	aryl hydrocarbon receptor	leptomycin B inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]	decreases reaction / increases degradation	protein	10497241
C038753	317	APAF1 APAF-1 CED4	apoptotic peptidase activating factor 1	[leptomycin B co-treated with TP53 gene mutant form] results in increased expression of APAF1 mRNA	affects cotreatment / increases expression	mRNA	20803015
C038753	367	AR AIS DHTR HUMARA HYSP1 KD NR3C4 SBMA SMAX1 TFM	androgen receptor	leptomycin B inhibits the reaction [SB 216763 results in decreased localization of AR protein]	decreases localization / decreases reaction	protein	21980429
C038753	581	BAX BCL2L4	BCL2-associated X protein	leptomycin B inhibits the reaction [Tretinoin results in increased expression of BAX protein]	decreases reaction / increases expression	protein	14592536
C038753	596	BCL2 Bcl-2 PPP1R50	B-cell CLL/lymphoma 2	leptomycin B inhibits the reaction [Tretinoin results in decreased expression of BCL2 protein]	decreases expression / decreases reaction	protein	14592536
C038753	598	BCL2L1 BCL-XL/S BCL2L BCLX BCLXL BCLXS Bcl-X PPP1R52 bcl-xL bcl-xS	BCL2-like 1	leptomycin B inhibits the reaction [Tretinoin results in decreased expression of BCL2L1 protein]	decreases expression / decreases reaction	protein	14592536
C038753	329	BIRC2 API1 HIAP2 Hiap-2 MIHB RNF48 c-IAP1 cIAP1	baculoviral IAP repeat containing 2	leptomycin B affects the localization of BIRC2 protein	affects localization	protein	15265700
C038753	330	BIRC3 AIP1 API2 CIAP2 HAIP1 HIAP1 MALT2 MIHC RNF49 c-IAP2	baculoviral IAP repeat containing 3	leptomycin B affects the localization of BIRC3 protein	affects localization	protein	15265700
C038753	332	BIRC5 API4 EPR-1	baculoviral IAP repeat containing 5	[leptomycin B co-treated with TP53 gene mutant form] results in increased expression of BIRC5 mRNA	affects cotreatment / increases expression	mRNA	20803015
C038753	332	BIRC5 API4 EPR-1	baculoviral IAP repeat containing 5	leptomycin B results in decreased expression of BIRC5 mRNA	decreases expression	mRNA	20803015
C038753	332	BIRC5 API4 EPR-1	baculoviral IAP repeat containing 5	leptomycin B results in decreased expression of BIRC5 protein	decreases expression	protein	20803015
C038753	332	BIRC5 API4 EPR-1	baculoviral IAP repeat containing 5	TP53 gene mutant form inhibits the reaction [leptomycin B results in decreased expression of BIRC5 protein]	decreases expression / decreases reaction	protein	20803015
C038753	672	BRCA1 BRCAI BRCC1 BROVCA1 IRIS PNCA4 PPP1R53 PSCP RNF53	breast cancer 1, early onset	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of BRCA1 mRNA	affects cotreatment / decreases expression	mRNA	20803015
C038753	672	BRCA1 BRCAI BRCC1 BROVCA1 IRIS PNCA4 PPP1R53 PSCP RNF53	breast cancer 1, early onset	leptomycin B results in decreased expression of BRCA1 mRNA	decreases expression	mRNA	20803015
C038753	7832	BTG2 PC3 TIS21	BTG family, member 2	leptomycin B results in increased expression of BTG2 mRNA	increases expression	mRNA	20803015
C038753	6347	CCL2 GDCF-2 HC11 HSMCR30 MCAF MCP-1 MCP1 SCYA2 SMC-CF	chemokine (C-C motif) ligand 2	leptomycin B results in increased secretion of CCL2 protein	increases secretion	protein	21967610
C038753	6347	CCL2 GDCF-2 HC11 HSMCR30 MCAF MCP-1 MCP1 SCYA2 SMC-CF	chemokine (C-C motif) ligand 2	polydatin inhibits the reaction [leptomycin B results in increased secretion of CCL2 protein]	decreases reaction / increases secretion	protein	21967610
C038753	9133	CCNB2 HsT17299	cyclin B2	leptomycin B results in decreased expression of CCNB2 mRNA	decreases expression	mRNA	20803015
C038753	9134	CCNE2 CYCE2	cyclin E2	leptomycin B results in decreased expression of CCNE2 mRNA	decreases expression	mRNA	20803015
C038753	993	CDC25A CDC25A2	cell division cycle 25A (EC:3.1.3.48)	leptomycin B results in decreased expression of CDC25A mRNA	decreases expression	mRNA	20803015
C038753	995	CDC25C CDC25 PPP1R60	cell division cycle 25C (EC:3.1.3.48)	leptomycin B results in decreased expression of CDC25C mRNA	decreases expression	mRNA	20803015
C038753	983	CDK1 CDC2 CDC28A P34CDC2	cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22)	leptomycin B results in decreased expression of CDK1 mRNA	decreases expression	mRNA	20803015
C038753	1026	CDKN1A CAP20 CDKN1 CIP1 MDA-6 P21 SDI1 WAF1 p21CIP1	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	leptomycin B results in increased expression of CDKN1A mRNA	increases expression	mRNA	20803015
C038753	1026	CDKN1A CAP20 CDKN1 CIP1 MDA-6 P21 SDI1 WAF1 p21CIP1	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	leptomycin B results in increased expression of CDKN1A protein	increases expression	protein	20803015
C038753	1026	CDKN1A CAP20 CDKN1 CIP1 MDA-6 P21 SDI1 WAF1 p21CIP1	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	TP53 gene mutant form inhibits the reaction [leptomycin B results in increased expression of CDKN1A protein]	decreases reaction / increases expression	protein	20803015
C038753	1111	CHEK1 CHK1	checkpoint kinase 1 (EC:2.7.11.1)	leptomycin B results in decreased expression of CHEK1 mRNA	decreases expression	mRNA	20803015
C038753	11200	CHEK2 CDS1 CHK2 HuCds1 LFS2 PP1425 RAD53 hCds1	checkpoint kinase 2 (EC:2.7.11.1)	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of CHEK2 mRNA	affects cotreatment / decreases expression	mRNA	20803015
C038753	3627	CXCL10 C7 IFI10 INP10 IP-10 SCYB10 crg-2 gIP-10 mob-1	chemokine (C-X-C motif) ligand 10	acteoside promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein]	decreases secretion / increases reaction	protein	21967610
C038753	3627	CXCL10 C7 IFI10 INP10 IP-10 SCYB10 crg-2 gIP-10 mob-1	chemokine (C-X-C motif) ligand 10	leptomycin B results in decreased secretion of CXCL10 protein	decreases secretion	protein	21967610
C038753	3627	CXCL10 C7 IFI10 INP10 IP-10 SCYB10 crg-2 gIP-10 mob-1	chemokine (C-X-C motif) ligand 10	Quercetin promotes the reaction [leptomycin B results in decreased secretion of CXCL10 protein]	decreases secretion / increases reaction	protein	21967610
C038753	1786	DNMT1 ADCADN AIM CXXC9 DNMT HSN1E MCMT	DNA (cytosine-5-)-methyltransferase 1 (EC:2.1.1.37)	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of DNMT1 mRNA	affects cotreatment / decreases expression	mRNA	20803015
C038753	1786	DNMT1 ADCADN AIM CXXC9 DNMT HSN1E MCMT	DNA (cytosine-5-)-methyltransferase 1 (EC:2.1.1.37)	leptomycin B results in decreased expression of DNMT1 mRNA	decreases expression	mRNA	20803015
C038753	1869	E2F1 E2F-1 RBAP1 RBBP3 RBP3	E2F transcription factor 1	leptomycin B results in decreased expression of E2F1 mRNA	decreases expression	mRNA	20803015
C038753	1871	E2F3 E2F-3	E2F transcription factor 3	leptomycin B results in increased expression of E2F3 mRNA	increases expression	mRNA	20803015
C038753	9538	EI24 EPG4 PIG8 TP53I8	etoposide induced 2.4	leptomycin B results in increased expression of EI24 mRNA	increases expression	mRNA	20803015
C038753	2099	ESR1 ER ESR ESRA ESTRR Era NR3A1	estrogen receptor 1	leptomycin B inhibits the reaction [Estradiol results in increased degradation of ESR1 protein]	decreases reaction / increases degradation	protein	15899841
C038753	1647	GADD45A DDIT1 GADD45	growth arrest and DNA-damage-inducible, alpha	leptomycin B results in increased expression of GADD45A mRNA	increases expression	mRNA	20803015
C038753	3014	H2AFX H2A.X H2A/X H2AX	H2A histone family, member X	leptomycin B promotes the reaction [bortezomib results in increased expression of H2AFX protein modified form]	increases expression / increases reaction	protein	16778179
C038753	3099	HK2 HKII HXK2	hexokinase 2 (EC:2.7.1.1)	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of HK2 mRNA	affects cotreatment / decreases expression	mRNA	20803015
C038753	3569	IL6 BSF2 HGF HSF IFNB2 IL-6	interleukin 6 (interferon, beta 2)	[leptomycin B co-treated with TP53 gene mutant form] results in increased expression of IL6 mRNA	affects cotreatment / increases expression	mRNA	20803015
C038753	3576	IL8 CXCL8 GCP-1 GCP1 LECT LUCT LYNAP MDNCF MONAP NAF NAP-1 NAP1	interleukin 8	acteoside inhibits the reaction [leptomycin B results in increased secretion of IL8 protein]	decreases reaction / increases secretion	protein	21967610
C038753	3576	IL8 CXCL8 GCP-1 GCP1 LECT LUCT LYNAP MDNCF MONAP NAF NAP-1 NAP1	interleukin 8	leptomycin B results in increased secretion of IL8 protein	increases secretion	protein	21967610
C038753	3576	IL8 CXCL8 GCP-1 GCP1 LECT LUCT LYNAP MDNCF MONAP NAF NAP-1 NAP1	interleukin 8	Quercetin inhibits the reaction [leptomycin B results in increased secretion of IL8 protein]	decreases reaction / increases secretion	protein	21967610
C038753	57913			leptomycin B results in increased expression of LRDD mRNA	increases expression	mRNA	20803015
C038753	4193	MDM2 ACTFS HDMX hdm2	MDM2 oncogene, E3 ubiquitin protein ligase	leptomycin B results in increased expression of MDM2 mRNA	increases expression	mRNA	20803015
C038753	4194	MDM4 HDMX MDMX MRP1	Mdm4 p53 binding protein homolog (mouse)	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of MDM4 mRNA	affects cotreatment / decreases expression	mRNA	20803015
C038753	4790	NFKB1 EBP-1 KBF1 NF-kB1 NF-kappa-B NF-kappaB NFKB-p105 NFKB-p50 NFkappaB p105 p50	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1	[leptomycin B co-treated with TP53 gene mutant form] results in increased expression of NFKB1 mRNA	affects cotreatment / increases expression	mRNA	20803015
C038753	3164	NR4A1 GFRP1 HMR N10 NAK-1 NGFIB NP10 NUR77 TR3	nuclear receptor subfamily 4, group A, member 1	leptomycin B inhibits the reaction [Tretinoin affects the localization of [NR4A1 protein binds to RXRA protein]]	affects binding / affects localization / decreases reaction	protein	14592536
C038753	9055	PRC1 ASE1	protein regulator of cytokinesis 1	leptomycin B results in decreased expression of PRC1 mRNA	decreases expression	mRNA	20803015
C038753	5578	PRKCA AAG6 PKC-alpha PKCA PRKACA	protein kinase C, alpha (EC:2.7.11.13)	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of PRKCA mRNA	affects cotreatment / decreases expression	mRNA	20803015
C038753	9232	PTTG1 EAP1 HPTTG PTTG TUTR1	pituitary tumor-transforming 1	leptomycin B results in decreased expression of PTTG1 mRNA	decreases expression	mRNA	20803015
C038753	6199	RPS6KB2 KLS P70-beta P70-beta-1 P70-beta-2 S6K-beta2 S6K2 SRK STK14B p70(S6K)-beta p70S6Kb	ribosomal protein S6 kinase, 70kDa, polypeptide 2 (EC:2.7.11.1)	leptomycin B results in decreased activity of RPS6KB2 protein	decreases activity	protein	12087098
C038753	6256	RXRA NR2B1	retinoid X receptor, alpha	leptomycin B inhibits the reaction [Tretinoin affects the localization of [NR4A1 protein binds to RXRA protein]]	affects binding / affects localization / decreases reaction	protein	14592536
C038753	27244	SESN1 PA26 SEST1	sestrin 1	leptomycin B results in increased expression of SESN1 mRNA	increases expression	mRNA	20803015
C038753	6775	STAT4 SLEB11	signal transducer and activator of transcription 4	leptomycin B affects the localization of STAT4 protein	affects localization	protein	15004198
C038753	6789	STK4 KRS2 MST1 TIIAC YSK3	serine/threonine kinase 4 (EC:2.7.11.1)	leptomycin B promotes the reaction [bortezomib results in increased activity of STK4 protein]	increases activity / increases reaction	protein	16778179
C038753	8795	TNFRSF10B CD262 DR5 KILLER KILLER/DR5 TRAIL-R2 TRAILR2 TRICK2 TRICK2A TRICK2B TRICKB ZTNFR9	tumor necrosis factor receptor superfamily, member 10b	leptomycin B results in increased expression of TNFRSF10B mRNA	increases expression	mRNA	20803015
C038753	8793	TNFRSF10D CD264 DCR2 TRAIL-R4 TRAILR4 TRUNDD	tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain	[leptomycin B co-treated with TP53 gene mutant form] results in increased expression of TNFRSF10D mRNA	affects cotreatment / increases expression	mRNA	20803015
C038753	8793	TNFRSF10D CD264 DCR2 TRAIL-R4 TRAILR4 TRUNDD	tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain	leptomycin B results in increased expression of TNFRSF10D mRNA	increases expression	mRNA	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [leptomycin B results in increased expression of TP53 protein]	decreases reaction / increases expression	protein	19751709
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of BRCA1 mRNA	affects cotreatment / decreases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of CHEK2 mRNA	affects cotreatment / decreases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of DNMT1 mRNA	affects cotreatment / decreases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of HK2 mRNA	affects cotreatment / decreases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of MDM4 mRNA	affects cotreatment / decreases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of PRKCA mRNA	affects cotreatment / decreases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of TP63 mRNA	affects cotreatment / decreases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in increased expression of APAF1 mRNA	affects cotreatment / increases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in increased expression of BIRC5 mRNA	affects cotreatment / increases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in increased expression of IL6 mRNA	affects cotreatment / increases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in increased expression of NFKB1 mRNA	affects cotreatment / increases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[leptomycin B co-treated with TP53 gene mutant form] results in increased expression of TNFRSF10D mRNA	affects cotreatment / increases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	leptomycin B inhibits the reaction [sodium arsenite affects the localization of TP53 protein]	affects localization / decreases reaction	protein	19010883
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	leptomycin B inhibits the reaction [sodium arsenite results in increased degradation of TP53 protein mutant form]	decreases reaction / increases degradation	protein	21454520
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	leptomycin B inhibits the reaction [TP53 protein results in increased susceptibility to trichostatin A]	decreases reaction / increases response to substance	protein	16467109
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	leptomycin B results in decreased degradation of TP53 protein	decreases degradation	protein	15625077
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	leptomycin B results in increased expression of TP53 protein	increases expression	protein	16467109 19751709
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	PCB 180 promotes the reaction [leptomycin B results in increased expression of TP53 protein]	increases expression / increases reaction	protein	19751709
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein]	decreases degradation / decreases reaction	protein	15625077
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	[sodium arsenite co-treated with leptomycin B] results in increased phosphorylation of TP53 protein	affects cotreatment / increases phosphorylation	protein	19010883
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	TP53 gene mutant form inhibits the reaction [leptomycin B results in decreased expression of BIRC5 protein]	decreases expression / decreases reaction	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	TP53 gene mutant form inhibits the reaction [leptomycin B results in increased expression of CDKN1A protein]	decreases reaction / increases expression	gene	20803015
C038753	7157	TP53 BCC7 LFS1 P53 TRP53	tumor protein p53	TP53 gene mutant form results in increased susceptibility to leptomycin B	increases response to substance	gene	20803015
C038753	8626	TP63 AIS B(p51A) B(p51B) EEC3 KET LMS NBP OFC8 RHS SHFM4 TP53CP TP53L TP73L p40 p51 p53CP p63 p73H p73L	tumor protein p63	[leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of TP63 mRNA	affects cotreatment / decreases expression	mRNA	20803015
C038753	8626	TP63 AIS B(p51A) B(p51B) EEC3 KET LMS NBP OFC8 RHS SHFM4 TP53CP TP53L TP73L p40 p51 p53CP p63 p73H p73L	tumor protein p63	leptomycin B results in decreased expression of TP63 mRNA	decreases expression	mRNA	20803015
C038753	126374	WTIP	Wilms tumor 1 interacting protein	leptomycin B results in decreased localization of WTIP protein	decreases localization	protein	14736876

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (5)

OMIM	preferred title	UniProt
#210900	Bloom syndrome; blm	P54132
#607948	Mycobacterium tuberculosis, susceptibility to	P11473
#601399	Platelet disorder, familial, with associated myeloid malignancy	Q01196
#607250	Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy; scan1	Q9NUW8
#277440	Vitamin d-dependent rickets, type 2a; vddr2a	P11473

KEGG DISEASE (10)

KEGG	disease name	UniProt
H00342	Tuberculosis	P11473 (related)
H00784	Localized autosomal recessive hypotrichosis	P11473 (related)
H01143	Vitamin D-dependent rickets	P11473 (related)
H00094	DNA repair defects	P54132 (related)
H00296	Defects in RecQ helicases	P54132 (related)
H00001	Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)	Q01196 (related) Q01196 (marker)
H00003	Acute myeloid leukemia (AML)	Q01196 (related) Q01196 (marker) Q13951 (marker)
H00004	Chronic myeloid leukemia (CML)	Q01196 (related)
H00978	Thrombocytopenia (THC)	Q01196 (related)
H00063	Spinocerebellar ataxia (SCA)	Q9NUW8 (related)

KNApSAcK Metabolite C00018636

Index Metabolite Species Human Protein / Gene in interactions Related Diseases

Metabolite

KNApSAcK Entry

Cluster

Link

ChEMBL

KEGG

CTD

Species

Summary

Plant class

Family

List (1)

* NCBI

Human Protein / Gene in interaction

11 ChEMBL Protein in interactions

CTD interaction (86)

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (5)

KEGG DISEASE (10)

Index

Metabolite

Species

Human Protein
/ Gene in interactions

Related Diseases